SG&A fell to $43.5 million from $74.8 million a year ago after ARS Pharmaceuticals killed broad consumer advertising, with both lines missing expectations and management reaffirming cash flow breakeven by the end of 2027. Neffy's US market share only moved to 5% from 4%, so the cheaper playbook has to prove it can still buy growth.
Latest Activity
SPRY Coverage
Berkshire Hathaway Picks Up More of Warren Buffett’s Favorite Media Stock
Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech stocks.
5 Stocks Under $10 Growing 50% Or More
Are you looking for low-cost stocks to add to your portfolio? Doing so can be a challenge. After all, stocks that trade with low share prices are often risky investment opportunities. That’s…
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying from an NFL team owner and a new CEO.